Nagesh Krish
Neurology · Union City, NJNPI 1710918115
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 1,985 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 12.4% — the pattern of someone who eats at a lot of different presentations. Among neurology clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,985 payments — averaging $23.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$6K
- EMD Serono, Inc.$4K
- Biogen$3K
- Lundbeck LLC$2K
- AstraZeneca$2K
- Amneal Pharmaceuticals LLC$2K
- plus $27K from 54 others
What the payments were for
- Speaking & faculty fees$850%
- Food & beverage$45,61499%
- Education$5361%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$46,234 in reported general payments places this provider in the 90th percentile of 521 neurology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GammakedImmune Globul G/Gly/Iga Avg 46 | 68 | $1,717,662 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 66 | $981,776 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 22 | $703,173 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 18 | $327,153 |
| Radicava OrsEdaravone | 16 | $226,548 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 13 | $198,527 |
| RexultiBrexpiprazole | 104 | $159,898 |
| NamzaricMemantine Hcl/Donepezil Hcl | 127 | $153,446 |
| XcopriCenobamate | 101 | $127,362 |
| UbrelvyUbrogepant | 82 | $118,885 |
| RytaryCarbidopa/Levodopa | 94 | $108,247 |
| HorizantGabapentin Enacarbil | 143 | $107,892 |
| BriviactBrivaracetam | 64 | $106,726 |
| Nurtec OdtRimegepant Sulfate | 74 | $99,411 |
| WakixPitolisant Hcl | 12 | $97,327 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Grifols USA, LLCGamunex-C | $132 | $981,77666 claims |
| PfizerOctagam, Nurtec Odt, Eliquis | $1,178 | $811,423107 claims |
| AbbVieNamzaric, Ubrelvy, Qulipta, Botox, Linzess | $5,730 | $383,187314 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid, Trintellix | $92 | $246,12686 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $402 | $159,898104 claims |
| SK Life Science, Inc.Xcopri | $1,440 | $127,362101 claims |
| Amneal Pharmaceuticals LLCRytary | $1,504 | $108,24794 claims |
| Neurocrine Biosciences, Inc.Ingrezza, Ongentys | $1,209 | $106,78227 claims |
| UCB, Inc.Briviact | $634 | $106,72664 claims |
| Harmony Biosciences LLCWakix | $554 | $97,32712 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $399 | $86,983245 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $683 | $84,82065 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 521 neurology providers in New Jersey.
Other neurology in Union City
- Steven BromleyAudubon$1.5M
- Mary Ann PiconeTeaneck$1.5M
- Fiona GuptaOradell$1.1M
- Matthew DavisMiddletown$567K
- Amos KatzEatontown$558K
- Monte PellmarFreehold$429K
- Marcie RabinSummit$387K
- Ashish KapoorBayonne$329K
- Mario VukicHackensack$310K
- Andrew SylvesterBridgewater$296K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.